Vikas Dandekar

Private equity investors have been investing large sums of money in hospitals. Certain types of hospital chains are delivering healthy returns for such investors.

Private equity investors have been investing large sums of money in hospitals. Certain types of hospital chains are delivering healthy returns for such investors.

Millions of diabetes patients have to take a painful insulin injection to keep sugar levels in control. Cipla is introducing Afrezza, an inhaled insulin, in India. Will doctors and patients buy this option?

AstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. The job cuts are part of a strategic restructuring due to loss of patent exclusivity and competition from generic drugs. The company continues to focus on new patented drugs for specialized treatments.

In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences. Udenyca will be sold in the US by Accord BioPharma, the specialty division of Intas Pharma.

From debunking myths about the Human Metapneumovirus (HMPV) to highlighting the importance of decentralized surveillance systems and rapid vaccine development, host Vikas Dandekar talks to Dr. Rajeev Jayadevan, Chairman, Research Cell, Kerala State IMA, Dr. Vinod Scaria, Chief Data Officer, Karkinos Healthcare, and Dr. Raches Ella, Chief Development Officer (CDO), Bharat Biotech. They discuss the evolving landscape of viral outbreaks, greater pandemic preparedness, and the need for vaccine innovations.

The drug has given promising results for the treatment of multiple myeloma, a rare form of blood cancer. The market for such drugs is expected to touch USD30 billion by the end of the decade. Although these are early days, can it take on the likes of J&J, Gilead, and Sanofi?

India reported 24 lakh TB cases last year, despite a government program launched in 2018 aiming to eliminate TB by 2025. This conversation examines critical advancements, including innovative diagnostics, improved treatment regimens, and public-private partnerships. Host Vikas Dandekar is joined by a distinguished panel comprising Dr. Urvashi Singh, Deputy Director General (TB) from the Ministry of Health and Family Welfare; Dr. Randeep Guleria, Former Director of AIIMS and a public health advocate; Dr. Alpa Dalal, Head of Pulmonary Medicine at Jupiter Hospital and Honorary Chest Physician at Sewri TB Hospital, Mumbai; and Mr. Sriram Natarajan, Director and CEO of Molbio Diagnostics. Together, they address key challenges such as stigma, treatment adherence, and the role of nutrition in recovery. Learn how India is leveraging technology, community involvement, and government initiatives to tackle one of its most pressing public health challenges. What progress has been made, where do we stand, and what’s next in the fight against tuberculosis? Tune in to find out.

Guillain-Barré Syndrome is a rare nerve disorder. It is not a communicable disease. Why is it spreading like a viral outbreak?

Guillain-Barré Syndrome is a rare nerve disorder. It is not a communicable disease. Why is it spreading like a viral outbreak?